Menu UF Health Home Menu
 

CME

Accreditation:This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the University of Florida College of Medicine. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 18.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The maximum number of 18.5 AMA PRA Category 1 Credits™  includes 15.5 designated for the Symposium, and 3.0 for a Pre-Symposium Workshop.

Objectives: Upon completion of this course, participants should be able to:

  • Outline the role, including timing, of fertility preservation for breast cancer patients.
  • Describe the most recent surgical approach to management of ductal carcinoma in situ
  • Describe current uses of DBT in the screening and diagnostic settings.
  • Apply DBT effectively to reduce failure in cancer detection in patients before the next mammogram.
  • Review controversies surrounding breast cancer screening.
  • Review the issue of breast cancer diagnosis.
  • Discuss what is meant by the term “overdiagnosis”.
  • Understand why estimates for overdiagnosis vary among different published studies.
  • Understand the difference between neoadjuvant and adjuvant therapies.
  • Identify molecular markers as prognostic and predictive tools.
  • Provide participants with the most recent information and guidance regarding the role of radiation and field selection post-neoadjuvant systemic therapy and discuss ongoing clinical trials addressing this issue.
  • Present and discuss ideas and controversies regarding radiation therapy tailored to molecular subtypes and discuss ongoing clinical trials.
  •  Understand how breast cancer in older women is biologically different from breast cancer in younger women.
  • Better understand how to treat older women with breast cancer, taking into account their unique clinical, biologic, and physiologic issues
  • Identify contributions from National Accreditation Program for Breast Centers consortium to improving the quality of care and monitoring of outcomes for patients with breast disease.
  • Assess the contribution of multi-modality breast cancer screening and imaging techniques and technologies, including mammography, CT, ultrasonography, and MRI.
  • Outline the role of radiotherapy and chemotherapy in early and metastatic breast cancer.
  • Review the prevalence of use of FDA-approved risk-reduction intervention strategies.
  • Discuss the reasons given by patients and physician for not using selective estrogen receptor modulators for breast cancer risk reduction and idenfity clinical strategies to improve their use.